ATE450496T1 - Verbindungen zur behandlung von stoffwechselstörungen - Google Patents

Verbindungen zur behandlung von stoffwechselstörungen

Info

Publication number: ATE450496T1
Authority: AT; Austria
Prior art keywords: sup; carbon atoms; ring; alkyl; hydrogen
Prior art date: 2003-04-22

Application number

AT04750364T

Other languages

English (en)

Inventor

Kirvin Hodge

Robert Kaufman

Albert Lee

Shalini Sharma

Borstel Reid Von

Original Assignee

Wellstat Therapeutics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-22

Filing date

2004-04-20

Publication date

2009-12-15

2004-04-20 Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp

2009-12-15 Application granted granted Critical

2009-12-15 Publication of ATE450496T1 publication Critical patent/ATE450496T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 3
208000030159 metabolic disease Diseases 0.000 title abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 6
125000000217 alkyl group Chemical group 0.000 abstract 4
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010006895 Cachexia Diseases 0.000 abstract 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
208000010706 fatty liver disease Diseases 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
-1 perfluoromethoxy Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04750364T 2003-04-22 2004-04-20 Verbindungen zur behandlung von stoffwechselstörungen ATE450496T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US46455303P	2003-04-22	2003-04-22
PCT/US2004/012142 WO2004093806A2 (en)	2003-04-22	2004-04-20	Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number	Publication Date
ATE450496T1 true ATE450496T1 (de)	2009-12-15

Family

ID=33310913

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04750364T ATE450496T1 (de)	2003-04-22	2004-04-20	Verbindungen zur behandlung von stoffwechselstörungen

Country Status (8)

Country	Link
US (1)	US7361686B2 (de)
EP (1)	EP1618086B1 (de)
JP (1)	JP4697973B2 (de)
CN (1)	CN1777576A (de)
AT (1)	ATE450496T1 (de)
CA (1)	CA2521589C (de)
DE (1)	DE602004024382D1 (de)
WO (1)	WO2004093806A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100965201B1 (ko) *	2001-06-12	2010-06-24	웰스테트 테라퓨틱스 코포레이션	대사 질환의 치료용 화합물
EP1601251B1 (de) *	2003-02-13	2014-11-12	Wellstat Therapeutics Corporation	Verbindungen zur behandlung von stoffwechselstörungen
DK1633340T3 (da) *	2003-04-15	2011-02-07	Wellstat Therapeutics Corp	Forbindelser til behandling af stofskifteforstyrrelser
US7442796B2 (en) *	2003-04-30	2008-10-28	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
CA2533890A1 (en) *	2003-08-20	2005-03-03	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
EP1868595B1 (de) *	2005-04-01	2012-01-11	Wellstat Therapeutics Corporation	Verbindungen zur behandlung von stoffwechselstörungen
UA95613C2 (ru) *	2005-11-09	2011-08-25	Уеллстат Терепьютикс Корпорейшн	Соединения для лечения расстройсв метаболизма
AU2007208127A1 (en) *	2006-01-25	2007-08-02	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
WO2007087505A2 (en) *	2006-01-25	2007-08-02	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
JP2009524686A (ja) *	2006-01-25	2009-07-02	ウェルスタットセラピューティクスコーポレイション	代謝障害を処置するための化合物
US20090176885A1 (en) *	2006-02-02	2009-07-09	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
US8044243B2 (en) *	2006-02-13	2011-10-25	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders
MX2008011022A (es) *	2006-02-28	2008-09-10	Wellstat Therapeutics Corp	Compuestos para el tratamiento de trastornos metabolicos.
WO2007117791A2 (en) *	2006-03-31	2007-10-18	Wellstat Therapeutics Corporation	Combination treatment of metabolic disorders
JP2009537559A (ja) *	2006-05-18	2009-10-29	ウェルスタットセラピューティクスコーポレイション	代謝障害の処置のための化合物
EP2026659A4 (de) *	2006-06-09	2010-06-30	Wellstat Therapeutics Corp	Verbindungen zur behandlung von stoffwechselstörungen
EP2240024A4 (de) *	2008-01-15	2014-05-21	Wellstat Therapeutics Corp	Verbindungen zur behandlung von stoffwechselstörungen
US8664433B2 (en) *	2008-05-05	2014-03-04	Wellstat Therapeutics Corporation	Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid
EP2365746B1 (de)	2008-11-04	2014-07-16	Wellstat Therapeutics Corporation	Synthese von (phenylalkyloxy)phenyloxobutansäuren

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3419952A1 (de) *	1984-05-28	1985-11-28	Bayer Ag, 5090 Leverkusen	Substituierte phenoxyphenylpropionsaeure-derivate
DE3621775A1 (de)	1986-03-13	1988-01-07	Thomae Gmbh Dr K	Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4897397A (en) *	1988-12-16	1990-01-30	Schering Corporation	Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents
US5084466A (en) *	1989-01-31	1992-01-28	Hoffmann-La Roche Inc.	Novel carboxamide pyridine compounds which have useful pharmaceutical utility
WO1995004025A1 (en) *	1993-07-29	1995-02-09	Chugai Seiyaku Kabushiki Kaisha	Tricarboxylic acid derivative having squalene synthetase inhibitor activity
US5466823A (en)	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
JP3880108B2 (ja) *	1994-11-02	2007-02-14	武田薬品工業株式会社	２，４−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
TW403748B (en) *	1994-11-02	2000-09-01	Takeda Chemical Industries Ltd	An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
ATE433964T1 (de)	2000-12-28	2009-07-15	Takeda Pharmaceutical	Alkansäurederivate, verfahren zu deren herstellung und deren verwendung
JP4148681B2 (ja) *	2000-12-28	2008-09-10	武田薬品工業株式会社	アルカン酸誘導体、その製造法および用途
KR100965201B1 (ko) *	2001-06-12	2010-06-24	웰스테트 테라퓨틱스 코포레이션	대사 질환의 치료용 화합물
US7645772B2 (en) *	2002-11-01	2010-01-12	Wellstat Therapeutics Corporation	Treatment of metabolic disorders
EP1601251B1 (de) *	2003-02-13	2014-11-12	Wellstat Therapeutics Corporation	Verbindungen zur behandlung von stoffwechselstörungen
DK1633340T3 (da)	2003-04-15	2011-02-07	Wellstat Therapeutics Corp	Forbindelser til behandling af stofskifteforstyrrelser
US7442796B2 (en) *	2003-04-30	2008-10-28	Wellstat Therapeutics Corporation	Compounds for the treatment of metabolic disorders

2004
- 2004-04-20 CN CNA2004800107323A patent/CN1777576A/zh active Pending
- 2004-04-20 CA CA2521589A patent/CA2521589C/en not_active Expired - Fee Related
- 2004-04-20 JP JP2006513151A patent/JP4697973B2/ja not_active Expired - Fee Related
- 2004-04-20 DE DE602004024382T patent/DE602004024382D1/de not_active Expired - Lifetime
- 2004-04-20 US US10/553,936 patent/US7361686B2/en not_active Expired - Lifetime
- 2004-04-20 EP EP04750364A patent/EP1618086B1/de not_active Expired - Lifetime
- 2004-04-20 AT AT04750364T patent/ATE450496T1/de not_active IP Right Cessation
- 2004-04-20 WO PCT/US2004/012142 patent/WO2004093806A2/en not_active Ceased

Also Published As

Publication number	Publication date
DE602004024382D1 (de)	2010-01-14
EP1618086A4 (de)	2007-05-09
CN1777576A (zh)	2006-05-24
HK1083462A1 (en)	2006-07-07
US20070105955A1 (en)	2007-05-10
US7361686B2 (en)	2008-04-22
WO2004093806A3 (en)	2005-04-07
WO2004093806A2 (en)	2004-11-04
JP2006524252A (ja)	2006-10-26
JP4697973B2 (ja)	2011-06-08
CA2521589C (en)	2011-11-01
EP1618086B1 (de)	2009-12-02
CA2521589A1 (en)	2004-11-04
EP1618086A2 (de)	2006-01-25

Legal Events

Date	Code	Title	Description
2010-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
CY1111310T1 (el)	2015-08-05	Ενωσεις για την αγωγη μεταβολικων διαταραχων
ATE526018T1 (de)	2011-10-15	Verbindungen zur behandlung von stoffwechselstörungen
WO2004073611A3 (en)	2004-11-25	Compounds for the treatment of metabolic disorders
ATE530066T1 (de)	2011-11-15	Verbindungen zur behandlung von stoffwechselstörungen
ATE450496T1 (de)	2009-12-15	Verbindungen zur behandlung von stoffwechselstörungen
UA95613C2 (ru)	2011-08-25	Соединения для лечения расстройсв метаболизма
WO2007087505A3 (en)	2007-12-13	Compounds for the treatment of metabolic disorders
WO2007095462A3 (en)	2008-05-02	Compounds for the treatment of metabolic disorders
WO2007137008A3 (en)	2008-08-28	Compounds for the treatment of metabolic disorders
TW200604175A (en)	2006-02-01	Ortho substituted aryl or heteroaryl amide compounds
TW200519088A (en)	2005-06-16	Aryl or heteroaryl amide compounds
NO20003399D0 (no)	2000-06-29	<Alfa>-amionoamidderivater som er nyttige som smertestillende midler
UA88772C2 (ru)	2009-11-25	Соединения для лечения расстройств метаболизма
ATE540675T1 (de)	2012-01-15	Verbindungen zur behandlung von stoffwechselstörungen
WO2007087504A3 (en)	2007-11-15	Compounds for the treatment of metabolic disorders
WO2007092729A3 (en)	2007-12-13	Compounds for the treatment of metabolic disorders
MXPA06000651A (es)	2006-03-30	Uso de derivados de indazol para el tratamiento de dolor neuropatico.